A clinical trial update dated April 29, 2026 reports on a study titled "Effects of Terlipressin and Somatostatin on Portal Pressure in Patients Undergoing Living Donor Liver Transplantation." The trial, registered as NCT07304466, is currently listed with a status of recruiting. The study phase is listed as not applicable. This update pertains to lypressin, a compound categorized under unapproved research status.
No outcome data or results have been posted for this trial according to the available record. The listing does not provide information on efficacy or safety findings at this stage, as recruitment is ongoing. The trial's stated focus is on portal pressure measurements in patients undergoing living donor liver transplantation, a specific clinical context for the compounds under investigation.
This brief reflects only the information contained in the trial registration record as of the stated date. Any future changes in status, phase, or posted results would represent separate updates. Readers interested in the broader context of lypressin, including its regulatory status and general background, can consult the compound overview for additional information.